Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Cancer Research UK funds University of Oxford scientists to develop ‘LynchVax’, the UK’s first vaccine aiming to prevent cancer in people with Lynch syndrome who have a much higher risk of developing several types of cancer.

Lynch syndrome is a heritable genetic condition. It is caused by an altered copy of one of a small number of our genes involved in processes that help repair our DNA. Failure to repair DNA can cause damage in genes that control growth, increasing the risk of cancer. Around 175,000–200,000 people are estimated to have Lynch syndrome in the UK and fewer than 5% (around 10,000 people) have been diagnosed.

People with Lynch syndrome have a higher overall risk of developing bowel cancer, as well as other types of cancer including womb cancer (also known as endometrial cancer) and ovarian cancer. Lynch syndrome is estimated to cause around 3% of bowel cancer cases in the UK every year, many of them in people under the age of 50. Up to 7 in 10 people with Lynch syndrome will develop bowel cancer in their lifetime.

The Oxford scientists, led by Associate Professor David Church, have been awarded up to £550,000 by Cancer Research UK to carry out the underpinning work to test the potential of a vaccine for patients with Lynch syndrome.If proved successful, the vaccine could in the future prevent cancer from happening in people with Lynch syndrome, rather than treating it once the cancer has already taken hold.

The first steps will see the team analysing cells that are showing early signs of becoming cancerous (called “pre-cancers”) from people with Lynch syndrome. They will use this information to determine which parts of a pre-cancer can be attacked by the immune system and whether a vaccine approach is likely to work to prevent cancer. With this knowledge, the researchers believe they could potentially design a vaccine that teaches the immune system to recognise pre-cancer cells and destroy them before they become cancer.

Cancer Research UK Advanced Clinician Scientist Fellow and co-lead of the LynchVax research team at University of Oxford, Associate Professor David Church, said:

“It is estimated that less than 5% of people with Lynch syndrome are aware that they have the condition. Yet it accounts for an estimated 1,300 cases of bowel cancer and increases the risk of other types of cancer in this population in the UK.

“We hope our research will lay the early foundations to potentially prevent these cases through vaccination, removing the fear of cancer from people whose chances of developing it in their lifetime are far higher.”

Professor of Molecular Genetics, Honorary Consultant Gastroenterologist and co-lead of the LynchVax research team at University of Oxford, Professor Simon Leedham, said:

“People with Lynch syndrome are at very high risk of developing bowel cancer, womb cancer and other cancers – so much so that they get invited to attend bowel screening appointments at a younger age than the rest of the UK population.

“LynchVax has the potential to reduce that risk. While our work is in its infancy, we are excited by the prospect of a vaccine that can potentially be used to prevent the multiple types of cancer that typically occur in people with Lynch syndrome and deliver tangible improvements in survival.”

The research team are also working with people with Lynch syndrome who have been helping to co-develop the project so far and will continue to be involved as the research progresses. Alongside the scientific work, the team will consult a larger number of people living with Lynch syndrome on their views about using vaccination to prevent cancer.

Member of the LynchVax patient and public involvement group, Helen White, said:

“I am delighted to be part of the patient and public involvement group working with the LynchVax research team that is developing this potentially life-changing vaccine for people like me with Lynch syndrome.

“As passionate advocates for involving people with lived experience in research, we fully endorse the plans to reach out to the wider Lynch syndrome community to gather their views on a cancer-preventing vaccine. This is a crucial step in preparing for future clinical trials.”

Cancer Research UK’s Chief Executive, Michelle Mitchell, said:

“Cancer vaccines continue to show promise in helping to create a world where people can live longer, better lives, free from the fear of cancer.

“Projects like LynchVax are a really important step forward into an exciting future, where cancers that occur in people with Lynch syndrome could potentially be prevented. This is one of many cancer vaccine projects Cancer Research UK is funding that we hope will reduce the number of cancer cases over the coming decades.”

Similar stories

Funding to create world's first ovarian cancer prevention vaccine

Researchers from Oxford have been awarded funding from Cancer Research UK to create the world’s first vaccine to prevent ovarian cancer.